Table VI.
Study [citation #] | Initial Abstinence Period | Prevention Medication Prevention Medication | Prevention Medication | Total N | Duration Relapse Prevention Treatment | Relative Risk | |
---|---|---|---|---|---|---|---|
Six Months | One Year | ||||||
Medication Assisted Initial Cessation | |||||||
Covey 2007 [122] | 4 weeks1 | Gum + Bupropion | Placebo Gum+ Bupropion | 146 | 16 weeks | 0.8 | 0.9 |
Covey 2007 [122] | 4 weeks1 | Gum | Placebo Gum | 143 | 16 weeks | 1.3 | 1.4 |
Croghan 2007 [123] | 7 days2 | Inhaler + Bupropion | Placebo Inhaler + Bupropion | 96 | 9 months | 1.2 | 1.1 |
Croghan 2007 [123] | 7 days2 | Inhaler | Placebo Inhaler | 94 | 9 months | 1.0 | 1.1 |
Croghan 2007 [123] | 7 days3 | Inhaler | Placebo Inhaler | 74 | 9 months | 1.6 | 1.5 |
Unaided Initial Cessation | |||||||
Killen [125] 1990 | 48hrs | Gum4 | No Gum5 | 1218 | 3 months | 1.2 | 1.2 |
Fortmann 1995 [124] | 24hrs | Gum + Self Help Materials | Self Help Materials | 521 | unstated | 1.6 | 1.3 |
Fortmann 1995 [124] | 24hrs | Gum | No gum | 523 | unstated | 1.3 | 1.3 |
Initial cessation facilitated by 8 weeks open label treatment of gum + bupropion + counseling
Initial cessation facilitated by 3 months open label treatment of inhaler + bupropion
Initial cessation facilitated by 3 months open label treatment of inhaler
Collapsed groups of instructional (n=301) and ad libitum gum (n=299) groups
Collapsed groups of placebo (n=309) and no gum (n=309) groups